Showing 7891-7900 of 10148 results for "".
- Encore Dermatology, Inc.: A New Specialty Dermatology Company Launcheshttps://practicaldermatology.com/news/encore-dermatology-inc-a-new-specialty-dermatology-company/2458942/Encore Dermatology, Inc. announced has begun to commercialize Hylatopic®, Tetrix™, and BenzEFoam™, three established topical dermatology products acquired from Valeant Pharmaceuticals North America, LLC and certain of its affiliates. Encore Dermatology, Inc. is a privately
- Senate Passes Bill to Repeal SGRhttps://practicaldermatology.com/news/senate-passes-bill-to-repeal-sgr/2458967/This week saw the end of the sustainable growth rate (SGR), with the US Senate passing the Medicare Access and CHIP Reauthorization Act (H.R.2) in a 92-8 vote and President Obama signing it into law. The bill, which the Hous
- Nerium International Announces Exclusive Usage of Anti-Aging Ingredient SIG-1273https://practicaldermatology.com/news/nerium-international-announces-exclusive-usage-of-anti-aging-ingredient-sig-1273/2458970/Nerium International added new ingredient, SIG-1273®, to the Optimera Formula of its Age-Defying Night and Day Creams. Engineered by Princeton University biochemist, Jeffry Stock, SIG-1273 is the result of 20 years of intensive biomedical skincare research, accordi
- Suneva Medical Introduces Regenica Recovery Gelhttps://practicaldermatology.com/news/suneva-medical-introduces-regenica-recovery-gel/2458983/Suneva Medical, Inc. introduced Regenica® Recovery Gel, a new addition to the Regenica® skin care system, during the American Academy of Dermatology Annual Meeting. Regenica® Recovery Gel is a soothing balm that is specially formulated to help quickly heal damaged skin. It infuses Mul
- Envy Medical Appoints Chief Marketing Officer to Executive Teamhttps://practicaldermatology.com/news/envy-medical-appoints-chief-marketing-officer-to-executive-team/2459002/Envy Medical Products, Inc., appointed Shauna Lahiri to the newly created role of Chief Marketing Officer. Ms. Lahiri brings a 17-year record of building successful global marketing strategies, building and launching new brands achieving leadership in mas
- Mikael Svensson Named Sr. VP of Sales/Marketing for Revision Skincarehttps://practicaldermatology.com/news/mikael-svensson-named-sr-vp-of-salesmarketing-for-revision-skincare/2459010/Revision Skincare appointed Mikael Svensson to the position of Senior Vice President of Sales and Marketing. In this new role, Mr. Svensson will oversee all Sales and Marketing activities, which include the strategic direction and leadership of Revis
- Provectus Biopharmaceuticals' Novel Synthesis Patent Application Allowed by Chinese Patent Officehttps://practicaldermatology.com/news/provectus-biopharmaceuticals-novel-synthesis-patent-application-allowed-by-chinese-patent-office/2459017/Provectus Biopharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company (
- ASDSA Names 2014 Patient Safety Hero Award Winnershttps://practicaldermatology.com/news/asdsa-named-2014-patient-safety-hero-award-winners/2459025/Honoring physicians and dermatologic societies whose notable efforts for greater patient safety in cosmetic procedures have made a difference last year, the American Society for Dermatologic Surgery Association (ASDSA) recently named the 2014 winners of its an
- Dr. Zein Obagi's New Book Presents the Art and Science of Skin Healthhttps://practicaldermatology.com/news/dr-zein-obagis-new-book-present-the-art-and-science-of-skin-health/2459023/Zein Obagi, MD, founder of ZO Skin Health, Inc., has published a new book, The Art of Skin Health Restoration and Rejuvenation: The Science of Clinical Practice, Second Edition (CRC Press, Dec 2014). In it, he reveals the Zein Ob
- Celsus Therapeutics Receives FDA Allowance of IND in Atopic Dermatitishttps://practicaldermatology.com/news/celsus-therapeutics-receives-fda-allowance-of-ind-in-atopic-dermatitis/2459026/Celsus Therapeutics will expand its clinical program in atopic dermatitis in the US, now that the FDA has allowed its Investigational New Drug Application (IND) for the clinical development of MRX-6 Cream 2% in patients with atopic dermatitis. The Com